Together with the B16F10 subcutaneous syngeneic tumor model, Cyr61 knockout resulted in fewer lung metastases and detectable circulating cancer cells, without affecting primary tumor growth, vascularity, hypoxia or pericyte coverage. This evidence concerns the gene CCN1 and cancer.